.Nature Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of clients with HER2+ enhanced breast cancer and also energetic or stable brain metastases presented consistent intracranial task and wide spread effectiveness of T-DXd.